³Ô¹ÏÍøÕ¾

Latest biotech News | Page 6

³Ô¹ÏÍøÕ¾ Reconstruction Fund (NRF) investment mandate released
Federal government backs the development of treatment for childhood brain cancer
Dimerix’s ACTION3 investigational new drug approved in China
Medical science a ‘priority area’ for new Industry Growth Program
AusBiotech weighs in on Australia’s RNA future
The Cell and Gene Catalyst call for change in submission to scope of practice review
Alterity Therapeutics raises $4.8 million in new placement
Orthocell announces final positive results of cell therapy in ‘tennis elbow’ study
Anteris reports positive 30-Day haemodynamic results from trial
Biotech headed to Hill for AusBiotech’s Policy Forum
Alterity Therapeutics announces presentation of new data for ATH434
US FDA grants Argenica Therapeutics’ ARG-007 orphan drug designation
ZAGENO Secures Esteemed Placement in the 2023 ProcureTech100 Elite
Neuren Pharmaceuticals completes Phelan-McDermid syndrome Phase 2 trial 
University of Queensland to establish world-leading mRNA laboratory
Telix says first patient dosed in ProstACT study of prostate cancer candidate
New report demonstrates benefit of long-term policy commitment
Clarity says recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
Imugene says next cohort reached in intravenous arms of monotherapy and combination study
New report quantifies the importance of R&D Tax Incentive on Australian economy
AusBiotech 2023 underway in Queensland
AusBiotech Board election result announced
New report quantifies impact of R&D Tax Incentive in Australia’s life sciences sector
It’s in our DNA: Australia’s biggest week in life sciences to advance biotech
Opthea announces leadership transition with the appointment of US-based executives
Emyria secures ethics endorsement for MDMA authorised prescriber application
AusBioInvest 2023 connects innovators with investment
AusBioInvest 2023 marks beginning of Australia’s biggest week in biotech
Anteris reports positive results from interim analysis of its US-EFS Trial for DurAVR THV
Imugene announces phase 1 clinical trial opens with onCARlytics CD19 virus technology
Top performing ASX life science companies 26 October
FDA grants Certa Therapeutics’ FT011 orphan drug designation for systemic sclerosis
AdAlta reports favourable patient tolerability after third dose in AD-214 extension study
Positive efficacy result for Immutep’s ‘efti’ in combination with MSD’s pembrolizumab
AusBioInvest 2023 programme launched
Shortage in regional nuclear medicine workforce attracts new financial support
J.P. Morgan’s chairman of investment banking announced as AusBioInvest keynote
Prescient to announce Phase 1b cancer trial results at world’s largest haematology conference
Victoria backing Australia’s first stem cell trial for rare genetic disorder
Australian biotechnologists and scientists celebrated in Prime Minister’s Prizes for Science
Oculus BioMed partners with The Centre for Eye Research Australia in a deal to develop ‘SwitchGene’
Arovella Therapeutics licences monoclonal antibody for cell therapy development
Posthumous recognition of benevolent billionaire
FivepHusion announces the appointment of experienced industry executive to its board
Training session on new Prescribed List products
CSL announces seven new Global Research Acceleration Initiative projects
Dimerix and Advanz Pharma enter agreement to commercialise DMX-200 in major markets